Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.65 CAD | -1.69% | -6.06% | +17.72% |
04-08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
03-14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.72% | 108M | |
+16.39% | 71.39B | |
+1.58% | 25.1B | |
-1.22% | 8.59B | |
+6.69% | 8.19B | |
-20.96% | 7.91B | |
+17.12% | 4.31B | |
-3.38% | 3.93B | |
-3.09% | 3.86B | |
+22.08% | 3.64B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Brief: Announcing that Vascepa Now Reimbursed by the Saskatchewan Drug Plan